Rapha Capital Management

About The Fund

Rapha Capital Management is an investment firm that focuses on driving the development of revolutionary ideas in the realms of medicine, healthcare, and technology. With a firm belief in identifying and nurturing groundbreaking concepts before they become widely recognized, Rapha invests predominantly in BioTech, HealthTech, Medical Devices, Healthcare, Consumer, and Pharmaceutical industries. Their investment range lies between $100,000 and $10,000,000 with a sweet spot at approximately $100,000. Specializing in Pre-Seed, Seed, and Series A funding stages, Rapha Capital Management provides an edge with its in-depth expertise and pioneering approach. The portfolio encompasses various companies including 3DBio Therapeutics, AngelMD, AsclepiX Therapeutics, and Bellicum Pharmaceuticals amongst others. The founder, Dr. Kevin Slawin, a notable oncologic and robotic surgeon, leverages his experiences in biotech and healthcare technologies to steer the company's investment strategy. Rapha Capital Management manages the Rapha Capital BioVentures Fund I and Rapha Capital PE Life Sciences Fund V & VI, through which they offer alternative asset management services. Rapha's investment philosophy is grounded by Slawin's track record of recognizing the potential in cellular immunotherapies and other innovative medical technologies, as evidenced by the success of Bellicum Pharmaceuticals. The team at Rapha comprises experts well-versed in scientific research and the development and commercialization of healthcare solutions, underscoring their commitment to fostering transformational therapies and technologies with the potential to address unmet clinical needs. Through their venture capital funds, they aim to provide support and guidance to entrepreneurs and early-stage companies with the passion and potential to bring paradigm-shifting ideas to fruition.